MacroPulse Logo

Sanofi Acquires Blueprint Medicines in $9.5 Billion Deal

Jun 2, 2025 (2 days ago)
Positive
News Image
Sanofi has agreed to acquire Blueprint Medicines for $9.5 billion, expanding its rare immunology portfolio.

Sanofi's Acquisition of Blueprint Medicines

  • Sanofi will acquire BPMC for $129 per share in cash plus up to $6 in milestone payments, totaling around $9.5 billion, a 40% premium over BPMC's 30-day average1
  • The acquisition aligns with Sanofi's strategy to strengthen its immunology and rare disease portfolio, complementing its existing Dupixent franchise1
  • Sanofi expects the deal to be immediately accretive to gross margin and accretive to business operating income and EPS after 20263

Ayvakit's Strong Performance

  • Ayvakit, BPMC's only approved treatment for systemic mastocytosis, generated $479 million in 2024 and $149.4 million in Q1 2025, up 61% year-over-year2
  • The drug is the only approved treatment for advanced and indolent systemic mastocytosis (ASM & ISM) in the U.S. and EU4

Strategic Implications

  • The acquisition adds BPMC's innovative pipeline, including BLU-808, an oral KIT inhibitor with potential beyond systemic mastocytosis1
  • Sanofi CEO Paul Hudson highlighted the deal as a strategic step forward, indicating Sanofi's capacity for further acquisitions4
MacroPulse Logo

Get the App

Use our app for a better experience

Install